BioCentury | Apr 25, 2020
Translation in Brief

Molecular Partners’ trifunctional COVID-19 therapeutic; plus F-star, Inscopix and Ocean Biomedical

...Models" ). New malaria vaccine target Ocean Biomedical Inc. showed that vaccines delivering P. falciparum GARP...
...comparison of antigens recognized by antibodies children resistant vs. susceptible to malaria identified P. falciparum GARP...
...red blood cells. In infected monkeys, prior immunization with recombinant protein or mRNA-encoded P. falciparum GARP...
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

...Imfinzi NSCLC Phase Ib/IIa AbbVie Inc. (NYSE:ABBV); argenx S.E. (Euronext:AGNX; NASDAQ:AGNX) ABBV-151 (ARGX-115) Leucine-rich repeat containing 32 (LRRC32; GARP)-TGFβ1...
BioCentury | Jun 10, 2019
Company News

Tilos takeout sees Merck tapping TGFβ to solve checkpoint resistance

...exercised an option to ARGX-115, a preclinical antibody targeting LRRC32 from argenx S.E. (Euronext:ARGX; NASDAQ:ARGX). LRRC32...
...She will move to a consulting role in the coming months. Targets: LRRC32 (GARP) - Leucine-rich repeat containing 32...
BioCentury | Mar 22, 2019
Company News

argenx gets first milestone payment from AbbVie for immuno-oncology therapy

...Inc. (NYSE:ABBV) exercised an option in 2018 to exclusively license the antibody targeting leucine-rich repeat containing 32 (LRRC32; GARP...
...Euronext:ARGX; NASDAQ:ARGX) (see "AbbVie Exercises Option for argenx Cancer Candidate" ). Sandi Wong, Staff Writer AbbVie Inc. argenx S.E. Leucine-rich repeat containing 32 (LRRC32) (GARP) Solid...
BioCentury | Aug 31, 2018
Company News

AbbVie exercises option for argenx cancer candidate

...an antibody targeting leucine-rich repeat containing 32 (LRRC32; GARP). Researchers at Catholic University Leuven found that mAbs against GARP...
...Euronext:ARGX; NASDAQ:ARGX), Breda, the Netherlands AbbVie Inc. (NYSE:ABBV), North Chicago, IL Business: Cancer Alicia Parker AbbVie Inc. argenx S.E. Leucine-rich repeat containing 32 (LRRC32) (GARP)...
BioCentury | Aug 22, 2018
Company News

AbbVie exercises option for argenx cancer candidate

...an antibody targeting leucine-rich repeat containing 32 (LRRC32; GARP). Researchers at Catholic University Leuven found that mAbs against GARP...
...€78 in Brussels on Wednesday and was up $4.32 to $91.87 on NASDAQ. Alicia Parker ARGX-115 AbbVie Inc. argenx S.E. Leucine-rich repeat containing 32 (LRRC32) (GARP)...
BioCentury | Oct 31, 2017
Distillery Techniques

Biomarkers

...5q31.1; and the region spanning chromosome 11 open reading frame 30 (C11orf30) and leucine-rich repeat containing 32 (LRRC32; GARP...
...for Molecular Medicine Berlin-Buch University of Cambridge Chromosome 11 open reading frame 30 (C11orf30) Filaggrin (FLG) Human leukocyte antigen (HLA) Leucine-rich repeat containing 32 (LRRC32) (GARP) Allergy...
BioCentury | Oct 24, 2017
Preclinical News

GWAS identify new risk loci in allergies and breast cancer

...gene cluster; the chromosome 11 open reading frame 30 (C11orf30) and leucine-rich repeat containing 32 ( LRRC32 ; GARP...
...for Molecular Medicine Berlin-Buch University of Cambridge Chromosome 11 open reading frame 30 (C11orf30) Filaggrin (FLG) Human leukocyte antigen (HLA) Leucine-rich repeat containing 32 (LRRC32) (GARP)...
BioCentury | Jul 6, 2017
Emerging Company Profile

LAPping up TGF beta

...indications. argenx S.E. ’s ARGX-115 is a preclinical mAb that targets leucine-rich repeat containing 32 ( LRRC32 ; GARP...
BioCentury | Apr 25, 2016
Company News

argenx, AbbVie deal

...exclusive option from argenx to license ARGX-115 , a mAb against leucine-rich repeat containing 32 ( LRRC32 ; GARP...
...Duve Institute at Catholic University Leuven (Leuven, Belgium). AbbVie will provide undisclosed funding for argenx’s GARP-related...
Items per page:
1 - 10 of 20